Source-grounded facts extracted from Alamar Biosciences, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Alamar Biosciences, Inc. reported the quarter ended March 31, 2026 results: revenue $26.0 million, net income $21.3 million.
“Proteomics dedicated to enabling the earliest detection of disease, today reported financial results for the quarter ended March 31, 2026. Recent Highlights • Generated $26.0 million of total revenue for the first quarter of 2026, an increase of 99% as compared to the corresponding period of 2025. • Launched two new products, NULISAseqTM Neuro 220 Panel and”
Alamar Biosciences, Inc.: Adopted amended and restated bylaws effective April 20, 2026 (effective 2026-04-20).
“Effective as of April 20, 2026, the Company adopted amended and restated bylaws (the “Restated Bylaws”) in connection with the closing of the IPO.”
Alamar Biosciences, Inc.: Filed amended and restated certificate of incorporation effective as of immediately prior to the closing of the IPO on April 20, 2026 (effective 2026-04-20).
“the Company filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware. The Company’s board of directors (the “Board”) and stockholders previously approved the Restated Certificate to be effective as of immediately prior to the closing of the IPO.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.